Loading...

We've got a brand new version of Simply Wall St! Try it out

dorsaVi

ASX:DVL
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DVL
ASX
A$7M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • dorsaVi has significant price volatility in the past 3 months.
DVL Share Price and Events
7 Day Returns
-11.8%
ASX:DVL
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-55.9%
ASX:DVL
50.9%
AU Biotechs
16.3%
AU Market
DVL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
dorsaVi (DVL) -11.8% -30.2% -41.2% -55.9% -93.3% -91.9%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • DVL underperformed the Biotechs industry which returned 50.9% over the past year.
  • DVL underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
DVL
Industry
5yr Volatility vs Market

Value

 Is dorsaVi undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for dorsaVi. This is due to cash flow or dividend data being unavailable. The share price is A$0.03.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for dorsaVi's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are dorsaVi's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:DVL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.02
ASX:DVL Share Price ** ASX (2019-11-17) in AUD A$0.03
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of dorsaVi.

ASX:DVL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:DVL Share Price ÷ EPS (both in AUD)

= 0.03 ÷ -0.02

-1.39x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • dorsaVi is loss making, we can't compare its value to the Global Biotechs industry average.
  • dorsaVi is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does dorsaVi's expected growth come at a high price?
Raw Data
ASX:DVL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.39x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for dorsaVi, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on dorsaVi's assets?
Raw Data
ASX:DVL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.03
ASX:DVL Share Price * ASX (2019-11-17) in AUD A$0.03
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:DVL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:DVL Share Price ÷ Book Value per Share (both in AUD)

= 0.03 ÷ 0.03

0.88x

* Primary Listing of dorsaVi.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • dorsaVi is good value based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess dorsaVi's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. dorsaVi has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is dorsaVi expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as dorsaVi has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is dorsaVi expected to grow at an attractive rate?
  • Unable to compare dorsaVi's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare dorsaVi's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare dorsaVi's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:DVL Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:DVL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:DVL Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-11-18
ASX:DVL Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 3 -2 -4
2019-03-31 3 -2 -4
2018-12-31 3 -2 -4
2018-09-30 3 -2 -4
2018-06-30 3 -3 -4
2018-03-31 4 -3 -4
2017-12-31 4 -3 -5
2017-09-30 4 -3 -4
2017-06-30 3 -3 -4
2017-03-31 3 -4 -4
2016-12-31 3 -4 -3
2016-09-30 3 -5 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if dorsaVi is high growth as no earnings estimate data is available.
  • Unable to determine if dorsaVi is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:DVL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from dorsaVi Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:DVL Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-11-18
ASX:DVL Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.02
2019-03-31 -0.02
2018-12-31 -0.02
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.03
2017-09-30 -0.03
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if dorsaVi will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine dorsaVi's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. dorsaVi's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. dorsaVi's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess dorsaVi's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
dorsaVi has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has dorsaVi performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare dorsaVi's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • dorsaVi does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare dorsaVi's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare dorsaVi's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
dorsaVi's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from dorsaVi Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:DVL Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 2.51 -4.02 5.72
2019-03-31 2.64 -3.84 5.88
2018-12-31 2.77 -3.66 6.04
2018-09-30 3.10 -3.69 6.37
2018-06-30 3.43 -3.73 6.70
2018-03-31 3.56 -4.16 6.89
2017-12-31 3.69 -4.59 7.08
2017-09-30 3.58 -4.23 6.69
2017-06-30 3.47 -3.88 6.30
2017-03-31 3.46 -3.63 6.20
2016-12-31 3.46 -3.39 6.11
2016-09-30 3.24 -4.31 6.53
2016-06-30 3.02 -5.24 6.96
2016-03-31 2.53 -6.20 7.51
2015-12-31 2.03 -7.17 8.06
2015-09-30 1.70 -7.60 8.47
2015-06-30 1.36 -8.04 8.87
2015-03-31 1.07 -7.25 8.07
2014-12-31 0.79 -6.47 7.27
2014-09-30 0.66 -5.01 5.75
2014-06-30 0.53 -3.56 4.22
2014-03-31 0.53 -2.73 3.31
2013-12-31 0.52 -1.89 2.40
2013-09-30 0.53 -1.78 2.26
2013-06-30 0.54 -1.66 2.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if dorsaVi has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if dorsaVi has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if dorsaVi improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess dorsaVi's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
dorsaVi has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is dorsaVi's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up dorsaVi's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • dorsaVi is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • dorsaVi's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of dorsaVi's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -8.2526193357352E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from dorsaVi Company Filings, last reported 4 months ago.

ASX:DVL Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 6.99 0.00 2.77
2019-03-31 6.99 0.00 2.77
2018-12-31 9.25 0.00 4.87
2018-09-30 9.25 0.00 4.87
2018-06-30 9.42 0.00 3.97
2018-03-31 9.42 0.00 3.97
2017-12-31 11.47 0.00 6.75
2017-09-30 11.47 0.00 6.75
2017-06-30 13.13 0.00 8.61
2017-03-31 13.13 0.00 8.61
2016-12-31 12.05 0.00 8.73
2016-09-30 12.05 0.00 8.73
2016-06-30 8.59 0.00 6.03
2016-03-31 8.59 0.00 6.03
2015-12-31 10.29 0.00 8.92
2015-09-30 10.29 0.00 8.92
2015-06-30 6.62 0.04 5.74
2015-03-31 6.62 0.04 5.74
2014-12-31 10.83 0.00 9.34
2014-09-30 10.83 0.00 9.34
2014-06-30 14.62 0.00 13.94
2014-03-31 14.62 0.00 13.94
2013-12-31 17.07 0.00 16.63
2013-09-30 17.07 0.00 16.63
2013-06-30 0.01 1.02 0.27
  • dorsaVi's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • dorsaVi has less than a year of cash runway based on current free cash flow.
  • dorsaVi has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.3% each year.
X
Financial health checks
We assess dorsaVi's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. dorsaVi has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is dorsaVi's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from dorsaVi dividends.
If you bought A$2,000 of dorsaVi shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate dorsaVi's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate dorsaVi's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:DVL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:DVL Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as dorsaVi has not reported any payouts.
  • Unable to verify if dorsaVi's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of dorsaVi's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as dorsaVi has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess dorsaVi's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can dorsaVi afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. dorsaVi has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of dorsaVi's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andrew Ronchi
COMPENSATION A$532,483
TENURE AS CEO 11.8 years
CEO Bio

Dr. Andrew James Ronchi, B.App.Sci. (Physio), PhD (RMIT Eng), GAICD co-founded dorsaVi Limited (Pro-Active Medical Pty Ltd.), has been its Chief Executive Officer since February 2008 and Executive Director since February 18, 2008. Dr. Ronchi developed the concept for the technology to assist with the treatment and management of lower back pain. He serves as a director of the newly formed Pro-Active Medical, having received venture capital funding from Starfish Ventures, a leading Australian Venture Capital fund. Dr. Ronchi has 19 years experience as a physiotherapist both as a 'hands on clinician' and a business developer and manager. He has successfully pioneered four physiotherapy clinics in Melbourne and has ceased clinical work to focus his efforts on the commercialization of this revolutionary concept. Dr. Ronchi has co-authored the core patent and is writing a second patent for the project. Dr. Ronchi holds a Bachelor of Applied Science in Physio from Latrobe University and has submitted his PhD thesis at RMIT University, related to the reliability and validity of the technology for measuring lower back movements.

CEO Compensation
  • Andrew's compensation has increased whilst company is loss making.
  • Andrew's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the dorsaVi management team in years:

5.1
Average Tenure
  • The average tenure for the dorsaVi management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Andrew Ronchi

TITLE
Co-Founder
COMPENSATION
A$532K
TENURE
11.8 yrs

Damian Connellan

TITLE
Chief Financial Officer
COMPENSATION
A$52K
TENURE
4.1 yrs

David Erikson

TITLE
Chief Technology Officer
COMPENSATION
A$208K
TENURE
1.4 yrs

Matt May

TITLE
General Manager
COMPENSATION
A$309K

Brendan Case

TITLE
Company Secretary
TENURE
6.1 yrs
Board of Directors Tenure

Average tenure of the dorsaVi board of directors in years:

11.3
Average Tenure
  • The average tenure for the dorsaVi board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Greg Tweedly

TITLE
Non-Executive Chairman
COMPENSATION
A$52K
TENURE
2 yrs

Andrew Ronchi

TITLE
Co-Founder
COMPENSATION
A$532K
TENURE
11.8 yrs

Ash Attia

TITLE
Independent Non-Executive Director
COMPENSATION
A$38K
TENURE
11.3 yrs

Caroline Elliott

TITLE
Independent Non Executive Director
COMPENSATION
A$38K
TENURE
2 yrs

Michael Panaccio

TITLE
Non-Executive Director
COMPENSATION
A$34K
TENURE
11.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
23. Dec 18 Buy Starfish Ventures Pty Ltd Company 21. Dec 18 21. Dec 18 17,262,292 A$0.06 A$1,001,203
23. Dec 18 Buy Michael Panaccio Individual 21. Dec 18 21. Dec 18 138,782 A$0.06 A$8,049
23. Dec 18 Buy Gregory Tweedly Individual 21. Dec 18 21. Dec 18 28,782 A$0.06 A$1,669
23. Dec 18 Buy Ashraf Attia Individual 21. Dec 18 21. Dec 18 70,379 A$0.06 A$4,082
20. Dec 18 Buy Andrew Ronchi Individual 13. Dec 18 13. Dec 18 465,327 A$0.06 A$26,989
20. Dec 18 Buy Andrew Ronchi Individual 20. Dec 18 20. Dec 18 3,200 A$0.06 A$186
X
Management checks
We assess dorsaVi's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. dorsaVi has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Imagine Owning dorsaVi (ASX:DVL) And Trying To Stomach The 89% Share Price Drop

Imagine if you held dorsaVi Ltd (ASX:DVL) for half a decade as the share price tanked 89%. … A Different Perspective dorsaVi shareholders are down 57% for the year, but the market itself is up 11%. … If you would like to research dorsaVi in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

Simply Wall St -

What Percentage Of dorsaVi Ltd (ASX:DVL) Shares Do Insiders Own?

See our latest analysis for dorsaVi ASX:DVL Ownership Summary, May 24th 2019 What Does The Lack Of Institutional Ownership Tell Us About dorsaVi? … Insider Ownership Of dorsaVi The definition of company insiders can be subjective, and does vary between jurisdictions. … But other times, private equity is selling out, having taking the company public.

Simply Wall St -

Easy Come, Easy Go: How dorsaVi (ASX:DVL) Shareholders Got Unlucky And Saw 92% Of Their Cash Evaporate

dorsaVi Ltd (ASX:DVL) shareholders should be happy to see the share price up 25% in the last month. … But spare a thought for the long term holders, who have held the stock as it bled value over the last five years. … It seems likely some shareholders believe that dorsaVi has the funding to invent a new product before too long.

Simply Wall St -

Is dorsaVi Ltd's (ASX:DVL) CEO Salary Justified?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Andrew Ronchi's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that dorsaVi Ltd has a market cap of AU$8.2m, and is paying total annual CEO compensation of AU$483k.

Simply Wall St -

Is dorsaVi Ltd's (ASX:DVL) Balance Sheet Strong Enough To Weather A Storm?

The direct benefit for dorsaVi Ltd (ASX:DVL), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is DVL growing fast enough to value financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

What Kind Of Shareholder Owns Most dorsaVi Ltd (ASX:DVL) Stock?

The big shareholder groups in dorsaVi Ltd (ASX:DVL) have power over the company. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … dorsaVi is not a large company by global standards.

Simply Wall St -

Here's What We Think About dorsaVi Ltd's (ASX:DVL) CEO Pay

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … We examined a group of similar sized companies, with market capitalizations of below AU$278m. … It would therefore appear that dorsaVi Ltd pays Andrew Ronchi more than the median CEO remuneration at companies of a similar size, in the same market

Simply Wall St -

What Does dorsaVi Ltd's (ASX:DVL) Ownership Structure Look Like?

Today, I will be analyzing dorsaVi Ltd’s (ASX:DVL) recent ownership structure, an important but not-so-popular subject among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Therefore, it is beneficial for us to examine DVL's ownership structure in more detail.

Simply Wall St -

Does dorsaVi Ltd's (ASX:DVL) Past Performance Indicate A Weaker Future?

Today I will examine dorsaVi Ltd's (ASX:DVL) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, in addition to how the rest of DVL's industry performed. … DVL is loss-making, with the most recent trailing twelve-month earnings of -AU$4.59m (from 31 December 2017), which compared to last year has become. … Each year, for the past five years DVL has seen an annual

Simply Wall St -

Does dorsaVi Ltd's (ASX:DVL) CEO Pay Compare Well With Peers?

Earnings is a powerful indication of DVL's ability to invest shareholders' funds and generate returns. … Therefore I will use earnings as a proxy of Ronchi's performance in the past year. … Normally I would look at market cap and earnings as a proxy for performance, however, DVL's negative earnings lower the usefulness of my formula.

Simply Wall St -

Company Info

Description

dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States. The company manufactures wearable sensors, software, and sophisticated algorithms to measure movement and muscle activation. It offers ViSafe, a wearable sensor technology that tracks, analyzes, and reports how employees move through their daily work lives and take the guess work out of workplace injuries and safety risks; and ViMove, a wearable sensor technology, which provides patient care and exercise plans, patient engagement and recovery programs, and new services and rehabilitation programs. The company also provides ViPerform, a wearable and wireless movement sensor technology that offers objective data to assess risk of sport injury and guide athletic training and recovery programs. dorsaVi Ltd was incorporated in 2008 and is based in Kew, Australia.

Details
Name: dorsaVi Ltd
DVL
Exchange: ASX
Founded: 2008
A$6,936,570
204,016,783
Website: http://www.dorsavi.com
Address: dorsaVi Ltd
86 Denmark Street,
Level 1,
Kew,
Victoria, 3101,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX DVL Ordinary Shares Australian Securities Exchange AU AUD 11. Dec 2013
CHIA DVL Ordinary Shares Chi-X Australia AU AUD 11. Dec 2013
Number of employees
Current staff
Staff numbers
34
dorsaVi employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:35
End of day share price update: 2019/11/17 00:00
Last estimates confirmation: 2019/06/03
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.